Related Experiment Video
Updated: Dec 25, 2025
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer
Danielle File1, Giuseppe Curigliano2, Lisa A Carey1
1University of North Carolina at Chapel Hill, Chapel Hill, NC.
Abstract:
Untreated, HER2+ disease is the most aggressive breast cancer phenotype; however, the development of multiple highly effective HER2-targeting drugs has transformed treatment and survival. These drugs include the anti-HER2 monoclonal antibodies trastuzumab and pertuzumab; small molecule inhibitors lapatinib, neratinib, and tucatinib; and antibody-drug conjugates trastuzumab emtansine (T-DM1) and now trastuzumab deroxtecan. More complex regimens using these drugs continue to improve outcomes, but the incremental benefits of these advances are often modest. Improved outcomes came from the addition of HER2-targeted therapies to conventional chemotherapy, beginning with trastuzumab, then pertuzumab added to trastuzumab, or with neratinib given for the year after trastuzumab. Neoadjuvant, or preoperative, administration of chemotherapy plus HER2-targeting allows surgical deescalation and tailoring treatment by pathologic complete response (pCR) to therapy. Patients with pCR after conventional therapy have excellent outcomes; what we now know is that the poorer outcomes associated with residual disease can be ameliorated with adjuvant T-DM1. However, as we have developed more complex, effective, and expensive therapy to maximize outcomes, it is also true that we are overtreating many patients. In stage I HER2+ breast cancer, there are excellent outcomes with paclitaxel plus trastuzumab or T-DM1 alone. Higher clinical stage HER2+ disease is still treated aggressively, although intrinsic subtype or activated immune tumor microenvironment may identify those with augmented treatment response or better outcome. It is likely that future strategies to escalate and de-escalate treatment with less chemotherapy, fewer anti-HER2 drugs, or shorter duration will depend upon integrated clinical and genomic modeling.
Insights
HER2-positive breast cancer treatment has advanced significantly with targeted therapies, improving survival but potentially leading to overtreatment in early stages. Future strategies aim to personalize treatment by integrating clinical and genomic data.
Area of Science:
- Oncology
- Pharmacology
- Genomics
Background:
- HER2-positive (HER2+) breast cancer is aggressive but has seen improved survival due to targeted therapies.
- Key HER2-targeting drugs include monoclonal antibodies (trastuzumab, pertuzumab), small molecule inhibitors (lapatinib, neratinib, tucatinib), and antibody-drug conjugates (trastuzumab emtansine [T-DM1], trastuzumab deroxtecan).
Purpose of the Study:
- To review the evolution and impact of HER2-targeted therapies in breast cancer treatment.
- To discuss the balance between treatment efficacy, complexity, cost, and the potential for overtreatment.
- To explore future directions in personalized HER2+ breast cancer treatment strategies.
Main Methods:
- Review of clinical advancements in HER2-targeted breast cancer therapy.
- Analysis of treatment outcomes based on clinical stage and response.
- Discussion of emerging strategies for treatment de-escalation and personalization.
Main Results:
- HER2-targeted therapies have transformed HER2+ breast cancer outcomes, with incremental benefits from complex regimens.
- Neoadjuvant therapy allows for surgical de-escalation and treatment tailoring based on pathologic complete response (pCR).
- Adjuvant T-DM1 can improve outcomes for patients with residual disease after neoadjuvant therapy; however, early-stage HER2+ breast cancer shows excellent outcomes with less intensive treatments, suggesting potential overtreatment.
Conclusions:
- While advanced HER2-targeted therapies have improved survival, they may lead to overtreatment, particularly in early-stage disease.
- Personalized treatment de-escalation strategies, informed by integrated clinical and genomic modeling, are crucial for optimizing care and minimizing unnecessary treatment.
- Identifying intrinsic subtypes and immune microenvironments may guide future treatment decisions for HER2+ breast cancer.
More Related Videos
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy